BioStem Technologies Reports 55% Q4 Revenue Drop, Swings to Net Loss
Summary
BioStem Technologies reported a significant decline in its fourth quarter 2025 financial results, with net revenue decreasing by 55% to $10.1 million and the company swinging to a GAAP net loss of ($11.3 million) or ($0.67) per share, compared to net income in the prior year. Full-year 2025 results also showed a substantial drop in revenue to $47.5 million from $69.7 million in 2024, leading to a full-year GAAP net loss of ($6.6 million). The company attributed the declines to reimbursement uncertainty and competitive pressure in the physician office market. Furthermore, BioStem provided a weak Q1 2026 revenue outlook, anticipating $5 million to $6 million, indicating continued challenges. These results are highly material for a company of BioStem's size, reflecting significant operational headwinds. Traders will be monitoring the integration of the BioTissue acquisition and the company's strategy to diversify into the hospital setting to mitigate ongoing pressures.
At the time of this announcement, BSEM was trading at $5.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $83.7M. The 52-week trading range was $3.09 to $15.74. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.